false 0000012208 0000012208 2019-12-05 2019-12-05 0000012208 us-gaap:CommonStockMember 2019-12-05 2019-12-05 0000012208 us-gaap:CommonClassBMember 2019-12-05 2019-12-05

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report: December 5, 2019

(Date of earliest event reported)

 

BIO-RAD LABORATORIES, INC.

(Exact name of registrant as specified in its charter)

 

Commission File Number: 1-7928

Delaware

  

94-1381833

(State or other jurisdiction

of incorporation)

  

(I.R.S. Employer

Identification No.)

1000 Alfred Nobel Dr.

Hercules, California 94547

(Address of principal executive offices, including zip code)

(510) 724-7000

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

  ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

  ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

  ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Class A Common Stock, Par Value $0.0001 per share

  

BIO

  

New York Stock Exchange

Class B Common Stock, Par Value $0.0001 per share

  

BIOb

  

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

ITEM 7.01 Regulation FD Disclosure

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) (“Bio-Rad”) today announced that on the evening of December 5, 2019, Bio-Rad detected a ransomware attack on its network. Bio-Rad immediately took certain systems offline as part of its comprehensive response to contain the activity. Work is ongoing to restore full system functionality as quickly as possible. Customers may experience delays in placing orders while Bio-Rad’s systems are down. At this time, there is no evidence of unauthorized transfer or misuse of data.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

BIO-RAD LABORATORIES, INC.

             

Date: December 6, 2019

  

 

By:

 

/s/ Timothy S. Ernst

 

 

 

Timothy S. Ernst

 

 

 

EVP, General Counsel and Secretary